Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-drive…

Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on ...
Fierce Biotech

AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...
BioSpace

AbbVie sinks talons into KRAS with right to buy Kestrel for up to $1.45B

AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for ...
Yahoo Finance

Boskalis and Keppel to sell KST and Maju to Rimorchiatori Mediterranei

Boskalis and its co-shareholder KS Investments Pte. Ltd. (Keppel) have signed an agreement relating to the sale of their harbor towage activities in Singapore and Malaysia to Rimorchiatori ...